The diagnosis of disseminated intravascular coagulation

Blood Reviews

Volumn 16, Issue 4, 2002, Pages 217-223

  Levi, Marcel ^a   De Jonge, Evert ^a   Meijers, Joost ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Disseminated intravascular coagulation; Fibrin; Fibrinogen; Fibrinolysis; Thrombin

Indexed keywords

FIBRIN; FIBRINOGEN; MOLECULAR MARKER; THROMBIN; BIOLOGICAL MARKER;

ALGORITHM; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; LABORATORY DIAGNOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBIN TIME; THROMBOCYTE COUNT; ANIMAL; BLOOD EXAMINATION;

ALGORITHMS; ANIMALS; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; HEMATOLOGIC TESTS; HUMANS;

EID: 0036883501     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00032-2     Document Type: Review

References (63)

1. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
2. Marder VJ, Feinstein D, Francis C, Colman R. Consumptive thrombohemorrhagic disorders. In: Colman RW et al., eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott Company; 1994: 1023.
3. Levi M, ten Cate H, van der Poll T, van Deventer S. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979.
4. Levi M, ten Cate H, van der Poll T. Disseminated intravascular coagulation: state of the art. Thromb Haemost 1999; 82: 695-705.
5. Pixley RA, De La Cadena R, Page JD et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-68.
6. Taylor FBJ, Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
7. Levi M, ten Cate H, Bauer KA et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120.
8. Biemond BJ, Levi M, ten Cate H et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995; 73: 223-230.
9. Shimura M, Wada H, Wakita Y et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997; 55: 169-174.
10. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-886.
11. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
12. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-5592.
13. Taylor FBJ, Chang A, Esmon CT et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coil infusion in the baboon. J Clin Invest 1987; 79: 918-925.
14. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
15. de Jonge E, Dekkers PE, Creasey AA et al. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activtion without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.
16. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FBJ, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2856.
17. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze Jr. GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-393.
18. Levi M, van der Poll T, de Jonge E, ten Cate H. Relative insuffciency of fibrinolysis in disseminated intravascular coagulation. Sepsis 2000; 3: 103-109.
19. Biemond BJ, Levi M, ten Cate H et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995; 88: 587-594.
20. Minnema MC, Pajkrt D, Wuillemin WA et al. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood 1998; 92: 3294-3301.
21. Braat EA, Levi M, Bos R et al. Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. J Lab Clin Med 1999; 134: 161-167.
22. Taylor Jr. FB, Toh CH, Hoots K, Wada H, Levi M. Towards a definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1027-1030.
23. Bick RL. Disseminated intravascular coagulation: Objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost 1996; 22: 69-88.
24. Cembrowski GS, Griffin JH, Mosher DF. Diagnostic efficacy of six plasma proteins in evaluating consumptive coagulopathies. Use of receiver operating characteristic curves to compare antithrombin III, plasminogen, alpha 2-plasmin inhibitor, fibronectin, prothrombin, and protein C. Arch Intern Med 1986; 146: 1997-2002.
25. Marx R, Meisner A. On hyperfibrinolysis and its treatment. Angiologica 1968; 5: 105-118.
26. Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired α2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70: 43-48.
27. Rodeghiero F, Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia 1994; 8(Suppl 2): S20-S26.
28. Fiegl M, Weltermann A, Stindl R, Fonatsch C, Lechner K, Gisslinger H. Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: Case report and review of the literature. Ann Hematol 1999; 78: 335-338.
29. Dempfle CE, Pfitzner SA, Dollman M, Huck K, Stehle G, Heene DL. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemost 1995; 74: 673-679.
30. Bredbacka S, Blomback M, Wiman B. Soluble fibrin: A predictor for the development and outcome of multiple organ failure. Am J Hematol 1994; 46: 289-294.
31. Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51: 186-191.
32. McCarron BI, Marder VJ, Kanouse JJ, Francis CW. A soluble fibrin standard: Comparable dose-response with immunologic and functional assays. Thromb Haemost 1999; 82: 145-148.
33. Shorr AF, Trotta RF, Alkins SA, Hanzel GS, Diehl LF. D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Med 1999; 25: 207-210.
34. Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999; 82: 673-683.
35. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 657-666.
36. McCarron BI, Marder VJ, Francis CW. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Thromb Haemost 1999; 82: 1722-1729.
37. Carr Jr. ME. Disseminated intravascular coagulation: Pathogenesis, diagnosis, and therapy. J Emerg Med 1987; 5: 311-322.
38. Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Reviews 1990; 4: 25-40.
39. Prisco D, Paniccia R, Bonechi F, Francalanci I, Abbate R, Gensini GF. Evaluation of new methods for the selective measurement of fibrin and fibrinogen degradation products. Thromb Res 1989; 56: 547-551.
40. Nakamura Y, Tomura S, Tachibana K, Chida Y, Marumo F. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992;38:90-96.
41. Rylatt DB, Blake AS, Cottis LE et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778.
42. Greenberg CS, Devine DV, McCrae KM. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads. Am J Clin Pathol 1987; 87: 94-100.
43. Carr JM, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol 1989; 91:280-287.
44. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097.
45. Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-2015.
46. ten Cate H, Bauer KA, Levi M et al. The activation of factor X and prothrombin by recombinant factor Vlla in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212.
47. Nossel HL, Yudelman I, Canfield RE et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53.
48. Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-α2-antiplasmin complex ratio. Haemostasis 1992; 22: 179-186.
49. Takahashi H, Wada K, Niwano H, Shibata A. Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1992; 3: 813-818.
50. Neame PB, Kelton JG, Walker IR, Stewart IO, Nossel HL, Hirsh J. Thrombocytopenia in septicemia: The role of disseminated intravascular coagulation. Blood 1980; 56: 88-92.
51. Akca S, Haii Michael P, de Medonca A, Suter PM, Levi M, Vincent JL. The time course of platelet counts in critically ill patients. Crit Care Med [in press].
52. Williams EC, Mosher DF. Disseminated intravascular coagulation. In: Hoffman R, Benz Jr. EJ, Shattil SJ, eds. Hamatology Basic Principles and Practice. New York: Churchill Livingstone; 1995: 1758.
53. Wada H, Wakita Y, Nakase T et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 1995; 74: 848-852.
54. Wuillemin WA, Fijnvandraat K, Derkx BH et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995; 74: 1436-1441.
55. Fijnvandraat K, Derkx B, Peters M et al. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73: 15-20.
56. Mesters RM, Helterbrand J, Utterback BG et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000; 28: 2209-2216.
57. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-228.
58. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27: 3-9.
59. Harpel PC. α2-Plasmin inhibitor and α2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest 1981; 68: 46-55.
60. Levi M, de Boer J, Roem D, ten Cate JW, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-α2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992; 67: 111-116.
61. Levi M, Roem D, Kamp AM, de Boer J, Hack CE, ten Cate J. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69: 141-146.
62. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75: 902-907.
63. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-I in posttrauma disseminated intravascular coagulation: Relationship to multiple organ dysfunction syndrome. Crit Care Med 1995; 23: 1835-1842.